Alkermes plc

greetings and welcome to the alchemy's third quarter 2020 earnings call my name is jim and i will be your operator for today's session please note that this conference is being recorded i'll now turn the floor over to sandy coombs vice president of investor relations welcome sandy thank you welcome to the alchemy plc conference call to discuss our financial results and business update for the quarter ended september 30 2020. thank you so much for joining us on on short notice we apologize for the technical difficulties

with our earlier scheduled call, but appreciate you all taking the time to join us at this time. With me today are Richard Pops, our CEO, Jim Fradies, our CFO, and Todd Nichols, our Chief Commercial Officer. During the Q&A section, we'll also be joined by Ian Brown, our FBP of Finance. Before we begin, I encourage everyone to go to the investor section at alchermes.com to find our press release and related financial tables, including a reconciliation of the gap to non-gap financial measures that we'll discuss today. We believe the non-GAAP financial results in conjunction with the GAAP results are useful in understanding the ongoing economics of our business. Our discussions during this conference call will include forward-looking statements. Actual results could differ materially from these forward-looking statements. Please see slide two of the accompanying presentation, our press release issued this morning, and our most recent annual and quarterly reports filed with the SEC. For important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. After our prepared remarks, we'll open the call for Q&A, and now I'll turn the call over to Richard.

That's great. Thank you, Sandy, and hello, everybody. We've got a lot of important updates to get to today, so I'd just like to start by noting our progress and some of the significant accomplishments we've achieved over the last several months. We are positioning the company for what we expect will be our next major phase of growth. The foundational pillars of that growth are our distinctive commercial capabilities, our R&D engine, and our focus on the efficient management of our business. Our third quarter results reflect strong commercial performance in a complex and dynamic environment and demonstrated resilience of our business and execution of our commercial strategy. We also achieved critical milestones in our ALCS 3831 and ALCS 4230 clinical development programs, and I'll talk about that more later in the call. While advancing these key priorities, we continue to efficiently manage expenses and drive non-GAAP profitability. As a result, today we've improved our financial expectations for the year and now expect to end the year with non-GAAP profitability back in line with our original expectations from February prior to the impact of COVID-19. Jim and Todd will provide additional detail on the performance and the outlook for the remainder of the year. And I'll end with an update on our clinical development activities. And with that, as a brief introduction, I'll hand the call over to Jim.